...
首页> 外文期刊>American Journal of Physiology >Oral administration of a PPAR-delta agonist to rodents worsens, not improves, maximal insulin-stimulated glucose transport in skeletal muscle of different fibers.
【24h】

Oral administration of a PPAR-delta agonist to rodents worsens, not improves, maximal insulin-stimulated glucose transport in skeletal muscle of different fibers.

机译:对啮齿动物口服给予PPAR-δ激动剂会使不同纤维骨骼肌中胰岛素刺激的最大葡萄糖转运恶化,但没有改善。

获取原文
获取原文并翻译 | 示例
           

摘要

Agonists targeting the nuclear receptor peroxisome proliferator-activated receptors (PPAR)-delta may be potential therapeutic agents for insulin-resistant related conditions, as they may be able to stimulate fatty acid (FA) oxidation and attenuate the accumulation of harmful lipid species in skeletal muscle. Several reports have demonstrated that PPAR-delta agonists improve whole body insulin sensitivity. However, whether these agonists exert their direct effects on glucose and FA metabolism in skeletal muscle, and specifically with different fiber types, is unknown. This study was undertaken to determine the effects of oral treatment with the PPAR-delta agonist, GW 501516, in conjunction with the administration of a high-saturated-fat diet on insulin-stimulated glucose transport in isolated oxidative (soleus) and glycolytic (epitrochlearis) rodent skeletal muscle in vitro. High-fat feeding significantly decreased maximal insulin-stimulated glucose transport in soleus, but not epitrochlearis muscle, and was associated with increased skeletal muscle diacylglycerol and ceramide content. Unexpectedly, treatment with the PPAR-delta agonist significantly reduced insulin-stimulated glucose transport in both soleus and epitrochlearis muscles, regardless of dietary fat content. The reduction in insulin-stimulated glucose transport induced by the agonist was associated with large increases in total muscle fatty acid translocase (FAT)/CD36protein content, but not diacylglycerol or ceramide contents. Agonist treatment did not alter the protein content of PPAR-delta, GLUT4, or insulin-signaling proteins (IRS-1, p85 PI3-K, Akt). Agonist treatment led to a small, but significant increase, in the oxidative capacity of glycolytic but not oxidative muscle. We propose that chronic treatment with the PPAR-delta agonist GW 501516 may induce or worsen insulin resistance in rodent skeletal muscle by increasing the capacity for FA transport across the sarcolemma without a sufficient compensatory increase in FA oxidation. However, an accumulation of diacylglycerol and ceramide, while associated with diet-induced insulin resistance, does not appear to be responsible for the agonist-induced reduction in insulin-stimulated glucose transport.
机译:靶向核受体过氧化物酶体增殖物激活受体(PPAR)-δ的激动剂可能是治疗胰岛素抵抗相关疾病的潜在治疗剂,因为它们可能能够刺激脂肪酸(FA)氧化并减弱骨骼中有害脂质种类的积累。肌肉。几篇报道表明,PPAR-δ激动剂可改善全身胰岛素敏感性。但是,这些激动剂是否对骨骼肌中的葡萄糖和FA代谢发挥直接作用,特别是对于不同的纤维类型,尚不清楚。进行这项研究来确定口服PPAR-δ激动剂GW 501516并结合高饱和脂肪饮食对胰岛素在单独的氧化(比目鱼)和糖酵解(上pi麻)中葡萄糖转运的影响)在体外啮齿动物骨骼肌。高脂喂养显着降低了比目鱼肌中最大的胰岛素刺激的葡萄糖转运,但不降低上斜肌,并且与骨骼肌二酰基甘油和神经酰胺含量增加有关。出乎意料的是,无论饮食中的脂肪含量如何,使用PPAR-δ激动剂进行治疗都会显着降低比目鱼肌和上睑肌的胰岛素刺激的葡萄糖转运。激动剂诱导的胰岛素刺激的葡萄糖转运减少与总肌肉脂肪酸转位酶(FAT)/ CD36蛋白含量的大幅增加有关,但与二酰基甘油或神经酰胺的含量无关。激动剂治疗不会改变PPAR-δ,GLUT4或胰岛素信号蛋白(IRS-1,p85 PI3-K,Akt)的蛋白质含量。激动剂治疗导致糖酵解而不是氧化性肌肉的氧化能力小但显着增加。我们建议用PPAR-δ激动剂GW 501516进行长期治疗可通过增加FA转运穿过肌膜的能力而在FA氧化中没有足够的补偿性增加来诱导或恶化啮齿动物骨骼肌的胰岛素抵抗。然而,虽然二酰基甘油和神经酰胺的积累与饮食诱导的胰岛素抵抗有关,但似乎不与激动剂诱导的胰岛素刺激的葡萄糖转运减少有关。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号